Charles Rhyee
Stock Analyst at TD Cowen
(1.98)
# 3,161
Out of 5,090 analysts
64
Total ratings
43.18%
Success rate
-8.05%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GDRX GoodRx Holdings | Maintains: Buy | $7 → $6 | $2.76 | +117.39% | 8 | Nov 10, 2025 | |
| CRL Charles River Laboratories International | Maintains: Buy | $205 → $197 | $184.60 | +6.72% | 6 | Nov 10, 2025 | |
| COR Cencora | Maintains: Buy | $350 → $400 | $336.93 | +18.72% | 1 | Nov 10, 2025 | |
| CI The Cigna Group | Maintains: Buy | $387 → $333 | $267.95 | +24.28% | 1 | Nov 4, 2025 | |
| CVS CVS Health | Maintains: Buy | $99 → $100 | $75.91 | +31.73% | 1 | Nov 3, 2025 | |
| CAH Cardinal Health | Maintains: Buy | $183 → $225 | $198.16 | +13.55% | 3 | Nov 3, 2025 | |
| OPCH Option Care Health | Maintains: Hold | $30 → $27 | $30.13 | -10.39% | 2 | Nov 3, 2025 | |
| IQV IQVIA Holdings | Downgrades: Hold | $206 → $215 | $224.71 | -4.32% | 2 | Nov 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Hold | $183 → $172 | $186.27 | -7.66% | 5 | Oct 24, 2025 | |
| MEDP Medpace Holdings | Maintains: Sell | $356 → $462 | $544.68 | -15.18% | 6 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $297 → $380 | $243.30 | +56.19% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $830 → $864 | $809.88 | +6.68% | 4 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $23 → $25 | $14.95 | +67.22% | 3 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $9 → $8 | $7.71 | +3.76% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.15 | +58.98% | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $4.11 | +1,116.55% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $13.70 | +308.76% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $11.99 | +2,235.28% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $4.09 | +1,122.49% | 2 | Jun 21, 2022 |
GoodRx Holdings
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.76
Upside: +117.39%
Charles River Laboratories International
Nov 10, 2025
Maintains: Buy
Price Target: $205 → $197
Current: $184.60
Upside: +6.72%
Cencora
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $336.93
Upside: +18.72%
The Cigna Group
Nov 4, 2025
Maintains: Buy
Price Target: $387 → $333
Current: $267.95
Upside: +24.28%
CVS Health
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $75.91
Upside: +31.73%
Cardinal Health
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $198.16
Upside: +13.55%
Option Care Health
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $30.13
Upside: -10.39%
IQVIA Holdings
Nov 3, 2025
Downgrades: Hold
Price Target: $206 → $215
Current: $224.71
Upside: -4.32%
ICON Public Limited Company
Oct 24, 2025
Maintains: Hold
Price Target: $183 → $172
Current: $186.27
Upside: -7.66%
Medpace Holdings
Oct 24, 2025
Maintains: Sell
Price Target: $356 → $462
Current: $544.68
Upside: -15.18%
Oct 7, 2025
Upgrades: Buy
Price Target: $297 → $380
Current: $243.30
Upside: +56.19%
Sep 24, 2025
Maintains: Buy
Price Target: $830 → $864
Current: $809.88
Upside: +6.68%
Nov 11, 2024
Maintains: Hold
Price Target: $23 → $25
Current: $14.95
Upside: +67.22%
Oct 31, 2024
Maintains: Hold
Price Target: $9 → $8
Current: $7.71
Upside: +3.76%
May 3, 2023
Maintains: Outperform
Price Target: $4 → $5
Current: $3.15
Upside: +58.98%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $4.11
Upside: +1,116.55%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $13.70
Upside: +308.76%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $11.99
Upside: +2,235.28%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $4.09
Upside: +1,122.49%